US Patent

US9693986 — Methods of reducing the risk of a cardiovascular event in a subject on statin therapy

Method of Use · Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2033-06-28 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods of reducing the risk of a cardiovascular event in a subject on statin therapy by administering eicosapentaenoic acid ethyl ester or a derivative thereof.

USPTO Abstract

In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2698 — Vascepa
U-2698 — Vascepa

Patent Metadata

Patent number
US9693986
Jurisdiction
US
Classification
Method of Use
Expires
2033-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Amarin Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.